Oxford Asset Management LLP Purchases New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

Oxford Asset Management LLP purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 16,687 shares of the company's stock, valued at approximately $730,000.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Revolution Medicines during the 3rd quarter worth approximately $801,000. Barclays PLC grew its holdings in Revolution Medicines by 187.1% during the third quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Revolution Medicines by 92.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 61,980 shares of the company's stock worth $2,711,000 after purchasing an additional 29,853 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Revolution Medicines by 9.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company's stock worth $84,467,000 after purchasing an additional 167,997 shares during the last quarter. Finally, Sandy Cove Advisors LLC acquired a new position in Revolution Medicines during the fourth quarter worth $1,837,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Insider Activity at Revolution Medicines

In related news, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Margaret A. Horn sold 3,058 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the sale, the chief operating officer now owns 153,533 shares in the company, valued at approximately $5,993,928.32. The trade was a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,660 shares of company stock valued at $650,406 over the last 90 days. Insiders own 8.00% of the company's stock.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.31 during trading on Thursday, hitting $40.69. The company's stock had a trading volume of 578,700 shares, compared to its average volume of 1,445,009. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of -11.28 and a beta of 1.37. The stock has a 50-day moving average price of $37.36 and a two-hundred day moving average price of $43.90.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). On average, equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wedbush restated an "outperform" rating and set a $67.00 target price on shares of Revolution Medicines in a report on Monday. Stifel Nicolaus reduced their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Needham & Company LLC restated a "buy" rating and set a $59.00 price objective on shares of Revolution Medicines in a research report on Tuesday, April 8th. Finally, UBS Group raised their price objective on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of "Buy" and a consensus price target of $66.67.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.